Literature DB >> 9099994

Methylglyoxal-modified arginine residues--a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells.

M E Westwood1, O K Argirov, E A Abordo, P J Thornalley.   

Abstract

Non-enzymatic glycosylation or glycation of proteins to form advanced glycation endproducts (AGE) has been proposed as a process which provides a signal for the degradation of proteins. Despite this, the AGE which act a recognition factor for receptor-mediated endocytosis and degradation of glycated proteins by monocytes and macrophages has not been identified. Methylglyoxal, a reactive alpha-oxoaldehyde and physiological metabolite, reacted irreversibly with arginine residues in proteins to form Ndelta-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine and Ndelta-(5-methyl-4-imidazolon-2-yl)ornithine residues. Human serum albumin minimally-modified with methylglyoxal (MG(min)-HSA) was bound by cell surface receptors of human monocytic THP-1 cells in vitro at 4 degrees C: the binding constant K(d) value was 377 +/- 35 nM and the number of receptors per cell was 5.9 +/- 0.2 X 10(5) (n = 12). N alpha-Acetyl-Ndelta-(5-hydro-5-methyl-4-imidazolon-2-yl)orni thine displaced MG(min)-HSA from THP-1 cells, suggesting that the Ndelta-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine residue was the receptor recognition factor. At 37 degrees C, MG(min)-HSA was internalised by THP-1 cells and degraded. Similar binding and degradation of human serum albumin modified by glucose-derived AGE was found but only when highly modified. MG(min)-HSA, therefore, is the first example of a protein minimally-modified by AGE-like compounds that binds specifically to monocyte receptors. The irreversible modification of proteins by methylglyoxal is a potent signal for the degradation of proteins by monocytic cells in which the arginine derivative, Ndelta-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine, is the receptor recognition factor. This factor is not present in glucose-modified proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099994     DOI: 10.1016/s0167-4889(96)00154-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  19 in total

1.  Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.

Authors:  Ricardo Gomes; Marta Sousa Silva; Alexandre Quintas; Carlos Cordeiro; António Freire; Paulino Pereira; Américo Martins; Estela Monteiro; Eduardo Barroso; Ana Ponces Freire
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

2.  Advanced glycation end products in myocardial reperfusion injury.

Authors:  Peter Celec; Július Hodosy; Peter Jáni; Pavol Janega; Matúš Kúdela; Marta Kalousová; Johana Holzerová; Vojtech Parrák; Lukáč Halčák; Tomáš Zima; Martin Braun; Ivan Pecháň; Ján Murín; Katarína Šebeková
Journal:  Heart Vessels       Date:  2011-05-12       Impact factor: 2.037

3.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose.

Authors:  P J Thornalley; A Langborg; H S Minhas
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

4.  Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence.

Authors:  Naila Ahmed; Paul J Thornalley
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

5.  Whole-Genome Sequencing of Finnish Type 1 Diabetic Siblings Discordant for Kidney Disease Reveals DNA Variants associated with Diabetic Nephropathy.

Authors:  Jing Guo; Owen J L Rackham; Niina Sandholm; Bing He; Anne-May Österholm; Erkka Valo; Valma Harjutsalo; Carol Forsblom; Iiro Toppila; Maija Parkkonen; Qibin Li; Wenjuan Zhu; Nathan Harmston; Sonia Chothani; Miina K Öhman; Eudora Eng; Yang Sun; Enrico Petretto; Per-Henrik Groop; Karl Tryggvason
Journal:  J Am Soc Nephrol       Date:  2020-01-09       Impact factor: 10.121

6.  Isolation and characterization of advanced glycation end products derived from the in vitro reaction of ribose and collagen.

Authors:  R G Paul; N C Avery; D A Slatter; T J Sims; A J Bailey
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

7.  Oleate, not ligands of the receptor for advanced glycation end-products, promotes proliferation of human arterial smooth muscle cells.

Authors:  C B Renard; B Askari; L A Suzuki; F Kramer; K E Bornfeldt
Journal:  Diabetologia       Date:  2003-11-01       Impact factor: 10.122

8.  Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.

Authors:  Y Yu; K F Hanssen; V Kalyanaraman; A Chirindel; A J Jenkins; A J Nankervis; P A Torjesen; H Scholz; T Henriksen; B Lorentzen; S K Garg; M K Menard; S M Hammad; J A Scardo; J R Stanley; M Wu; A Basu; C E Aston; T J Lyons
Journal:  BJOG       Date:  2012-08-20       Impact factor: 6.531

9.  Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2.

Authors:  Ebaa M Alzayadneh; Mark C Chappell
Journal:  Cell Signal       Date:  2014-09-19       Impact factor: 4.315

10.  Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes.

Authors:  Beatriz Duran-Jimenez; Darin Dobler; Sarah Moffatt; Naila Rabbani; Charles H Streuli; Paul J Thornalley; David R Tomlinson; Natalie J Gardiner
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.